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Abstract
Background: Betacellulin is a member of the epidermal growth factor family, expressed at the
highest levels predominantly in the pancreas and thought to be involved in islet neogenesis and
regeneration. Nonsynonymous coding variants were reported to be associated with type 2
diabetes in African American subjects. We tested the hypotheses that these previously identified
variants were associated with type 2 diabetes in African Americans ascertained in Arkansas and that
they altered insulin secretion in glucose tolerant African American subjects.
Methods: We typed three variants, exon1 Cys7Gly (C7G), exon 2 Leu44Phe (L44F), and exon 4
Leu124Met (L124M), in 188 control subjects and 364 subjects with type 2 diabetes. We tested for
altered insulin secretion in 107 subjects who had undergone intravenous glucose tolerance tests to
assess insulin sensitivity and insulin secretion.
Results: No variant was associated with type 2 diabetes, and no variant altered insulin secretion
or insulin sensitivity. However, an effect on lipids was observed for all 3 variants, and variant L124M
was associated with obesity measures.
Conclusion: We were unable to confirm a role for nonsynonymous variants of betacellulin in the
propensity to type 2 diabetes or to impaired insulin secretion.
Background
Type 2 diabetes (T2DM) has a substantial genetic compo-
nent, but identification of susceptibility genes has been
limited by the large number of loci and small effect size.
Defective insulin action is widely accepted as one element
in the progression of metabolic syndrome to impaired
glucose tolerance and T2DM, but increasing data support
a role for early β-cell dysfunction in the pathogenesis of
type 2 diabetes [1-3]. Impaired β-cell function predicts
future diabetes [4], and work from our laboratory [5] and
others [6,7] suggest that the ability of pancreatic β-cell to
compensate for prevailing insulin sensitivity is highly her-
itable. Mutations in β-cell transcription factors suggest
that control of both β-cell mass and insulin secretion may
Published: 25 July 2006
BMC Medical Genetics 2006, 7:62 doi:10.1186/1471-2350-7-62
Received: 16 May 2006
Accepted: 25 July 2006
This article is available from: http://www.biomedcentral.com/1471-2350/7/62
© 2006 Elbein et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
Page 2 of 8
(page number not for citation purposes)
play a role in the genetic susceptibility to β-cell failure and
T2DM [8].
Betacellulin (BTC) is one of the factors potentially con-
trolling β-cell growth. Although the BTC gene is located
on chromosome 4q13-q21, which is not a replicated
region of linkage to T2DM, BTC is nonetheless a strong
candidate for T2DM. BTC, which was isolated from insuli-
noma cells, is highly expressed in pancreas and intestine
[9]. BTC belongs to the epidermal growth factor (EGF)
family and appears to act through the EGF receptor,
although other receptors including ErbB-4 and perhaps a
specific BTC receptor have been proposed [10]. Several
models suggest that BTC can act to induce neogenesis of
β-cells with resultant improvement in glucose homeosta-
sis. Recombinant human BTC improved glucose tolerance
and increased the number of islet-like cell clusters in
alloxan-treated mice, suggesting increased islet neogenesis
from ductal cells [9]. Activin A and BTC together signifi-
cantly reduced plasma glucose, increased pancreatic β-cell
mass, and increased islet insulin content in streptozotocin
treated rats [11]. Rats treated with BTC alone after 90%
pancreatectomy also experienced increased β-cell mass,
increased islet insulin content, and improved glucose.
Finally, BTC induced differentiation of the pancreatic exo-
crine cell line AR42J into insulin secreting cells [12,13].
Silver et al. demonstrated that BTC was expressed in 9–24
week human fetal pancreas [14]. They established that the
human BTC gene contains 6 exons spanning at least 40
kb, of which the first 5 exons are translated. Three nonsyn-
onymous coding variants were identified: Cys7Gly (C7G)
in exon 1, Leu44Phe (L44F) in exon 2, and Leu124Met
(L124M) in exon 4. The C7G variant showed a 13% lower
minor allele frequency in African American cases (fre-
quency 0.32; n = 185) than in controls (frequency 0.45; n
= 149; p = 0.0004). Although no other variant was signif-
icantly associated with T2DM, and no variant was associ-
ated with T2DM in Caucasians, several haplotype
combinations, including haplotypes comprising alleles at
C7G and L44F, showed significant associations in African
American subjects [14].
Recently, Silver and colleagues [15] reported the associa-
tion of an intron 4 variant of BTC with decreased risk of
type 1 diabetes in a case control study of 100 Caucasian
cases and 282 Caucasian controls. This study was repli-
cated in 113 informative trios, and provided additional
evidence for BTC as a candidate for diabetes risk.
Based on these prior data and the strength of BTC as a can-
didate for the inherited β-cell defect that contributes to
T2DM, we tested the role of these 3 coding variants in Afri-
can American subjects ascertained in Arkansas in two
studies: a case-control study of diabetic individuals with a
family history of diabetes and normoglycemic control
individuals, and a second study of glucose tolerant indi-
viduals who had undergone detailed assessment of insu-
lin sensitivity and insulin secretion. We sought to test the
hypothesis that coding defects of the BTC gene predispose
to T2DM in African Americans and result in defective
insulin secretion in nondiabetic individuals at risk.
Methods
Experimental subjects
We genotyped 352 T2DM cases (188 male, 164 female)
and 182 controls (91 male, 91 female). Cases were drawn
primarily from University of Arkansas for Medical Sci-
ences and Central Arkansas Veterans Healthcare Systems
clinics, and were selected for a family history of diabetes
in at least one first-degree relative. Control individuals
were recruited from the general population, from other
ongoing studies, and from spouses of cases; all control
individuals had no family history of diabetes in a first
degree relative. Control individuals were selected for
either a normal 75 g oral glucose tolerance test, or when a
glucose tolerance test was not feasible, a random glucose
below 5.6 mmol/liter. Demographics of the case-control
population are shown in Table 1. Controls were younger
(p < 0.001) and leaner (p < 0.001) than cases at the time
of testing, but were not different in age at testing from the
age of diabetes diagnosis for cases. All subjects provided
written informed consent under protocols approved by
the University of Arkansas for Medical Sciences Institu-
tional Review Board.
Table 1: Demographics of African American Case Control Population
Trait Controls T2DM
Gender (Male/Female) 95/93 192/172
Age at visit (years) 42.6 ± 13.1 54.8 ± 12.6*
Age of diagnosis ---- 42.6 ± 11.9
Body Mass Index (kg/m2) 30.2 ± 7.2 32.7 ± 7.5*
Diabetic nephropathy (no nephropathy/nephropathy/unknown) ---- 126/152/88
Available demographic characteristics of case control population. See also Materials and Methods. Individuals with nephropathy had either 
microalbumin:creatinine ratios over 300, end stage renal disease, or elevated creatinines without another cause. Individuals without nephropathy 
had 10 years of T2DM with a microalbumin:creatinine ratio under 30. All other individuals, including those with microalbuminuria, were considered 
unknown. * Significantly different at p < 0.001.BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
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We examined 107 subjects (44 male, 63 female) who had
undergone frequently sampled intravenous glucose toler-
ance tests (FSIGT) under either a tolbutamide-modified
protocol (63 subjects) or an insulin-modified protocol
(44 subjects). Subjects were selected for a range of BMI
and family history of T2DM, but all had normal glucose
tolerance tests and no prior history of diabetes or gesta-
tional diabetes. Characteristics of the study population
that underwent FSIGT testing are shown in Table 2. Sub-
jects were in good health and on no medications known
to alter insulin sensitivity or secretion. Women were stud-
ied in the follicular phase of the menstrual cycle. Blood
pressure was measured using the automated Dinamap Pro
100 V2 (GE Healthcare Technologies, Waukesha, Wiscon-
sin), waist and hip circumference were measured at the
umbilicus and at greatest diameter, respectively, and
height and weight were measured on a wall mounted sta-
diometer and digital scale, respectively. Percent fat was
measured by dual X-ray absortiometry (DEXA) on a
Hologic QDR 4500 Elite (Hologic, Inc, Bedford, MA),
unless the subject was too large, in which case bioelectri-
cal impedence was measured. For each FSIGT protocol, we
obtained 3 baseline samples for glucose and insulin, after
which we infused 11.4 g/m2 glucose as D50 over 60 s.
Sampling was continued at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16,
and 19 min. At 20 min we gave either 125 mg/m2 of tolb-
utamide (tolbutamide-modified protocol), or because
tolbutamide became suddenly unavailable (no Federal
Drug Administration approved United States supplier)
during the study, we infused insulin at 0.04 U/kg, each
over 30 s. Sampling was continued at 22, 23, 24, 25, 27,
30, 40, 50, 70, 90, 100, 120, 150, and 180 min, and sub-
sequently at 30 min intervals to 240 min if the glucose
had not returned to baseline. In a subset of 40 individuals,
we raised the glucose to 25 mmol/l at the conclusion of
the FSIGT protocol, and maintained it for 30 min, at
which time a 5 g arginine bolus was administered over 60
s. Insulin was measured at times 0, 2, 3, 4, 6, 8, and 10
min relative to the arginine bolus. Arginine administered
at high glucose has been proposed as a surrogate measure
of β-cell mass [16].
Genotyping of the three betacellulin polymorphisms
We genotyped the 3 coding variants of the BTC gene: C7G
(Exon 1;rs28549760), L44F (Exon 2; no rs number), and
L124M (Exon 4; rs11938093). We designed primers
flanking each of the polymorphisms using Pyrosequenc-
ing Assay Design Software 1.0.6 (Biotage, Inc, Uppsula,
Sweden). L44F, L124M, and C7G variants were genotyped
using Pyrosequencing on a PSQ-96 machine according to
the manufacturer's methods (Biotage, Inc). Because of
some questions regarding the reliability of the C7G assay,
we confirmed the typing in 41 duplicate samples, and also
tested all questionable calls using a Sma1  restriction
enzyme digest that included an internal cutting site, fol-
lowed by separation on 2.5% agarose gels and scoring
from ethidium bromide stained gels. After redesign of the
C7G assay, no errors were detected in over 40 repeated
samples for each marker. PCR primers and conditions for
the each of the SNPs are shown in Table 3. All data were
in Hardy Weinberg Equilibrium.
Statistical analysis
Insulin sensitivity (SI) was calculated from FSIGT glucose
and insulin data using the MinMod Millenium software
[17,18]. Insulin secretion was measured as the acute 2
min – 10 min insulin response to the initial glucose bolus
(AIRg), and disposition index (DI) was calculated as SI
*AIRg, a measure of the β-cell response to insulin sensitiv-
ity [19].
Association of the three variants with T2DM were tested
primarily for allelic association using either chi-squared
or Fisher's Exact test, as implemented in either the 2by2
Table 2: Characteristics of African American Subjects Who Underwent Intravenous Glucose Tolerance Testing
Trait Mean ± standard deviation
Gender (Male/Female) 44/64
Age (years) 37.2 ± 9.4
Body mass index (kg/m2) 30.5 ± 6.4
Waist circumference (cm) 97.6 ± 19.9
Waist:Hip ratio 0.919 ± 0.108
Systolic blood pressure 106.4 ± 10.7
Diastolic blood pressure 63.1 ± 11.4
Protocol (tolbutamide/insulin) 60/30
Percent fat (DEXA) 32.1 ± 11.2
SI (× 10-4 min-1/μU/ml) 4.95 ± 9.17
Sg (min-1) 0.0194 ± 0.082
AIRg (pmol/l) 5013 ± 3996
Disposition Index 2590 ± 2608
Fasting glucose (mmol/l) 4.66 ± 0.56
Fasting insulin (pmol/l) 54.3 ± 36.8BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
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program [20] or the HaploView 3.2 program [21]. Haplo-
types were constructed from 2 and 3 locus combinations
using both HaploView 3.2 [21] and Phase 2.1 [22]. Global
significance was judged from the default 100 permuta-
tions. Impact of the three variants on quantitative traits in
glucose tolerant individuals who had undergone FSIGT
was tested using mixed effects models, in which ln-trans-
formed BMI and age were covariates and protocol type
(tolbutamide or insulin), gender, and genotype were fixed
factors. Traits AIRg, DI, SI, triglycerides, and cholesterol
were all ln-transformed to normality prior to analysis.
Marginal means were tested for significance and con-
verted back to the linear scale for presentation of results.
Previous studies have suggested that although tolbuta-
mide and insulin modified FSIGT are not interchangea-
ble, the results are strongly correlated and thus the
statistical method described here will be valid [23].
Because fewer than 5 individuals were homozygous for
the uncommon allele for both L124M and L44P variants,
we only examined carrier status for the quantitative traits
for both variants (for example, L124/L124 vs L124/M124
+ M124/M124).
Results
None of the three variants were associated with T2DM in
our population of 352 diabetic and 182 control individu-
als by allelic association (Table 4), nor when examined in
an exploratory analysis by genotype association (p > 0.4;
see Table 5). The three variants were not significantly cor-
related with each other (r2 < 0.05 for all pairs), and no
haplotype block was predicted using standard Gabriel def-
initions [24]. Variants L44F and L124M were in strong dis-
equilibrium by D' (D' = 0.93), whereas C7G was in only
modest disequilibrium with L44F (D' = 0.62) and not in
linkage disequilibrium with L124M (D' = 0.07). Given no
evidence for haplotype blocks with C7G in our data, we
chose to examine all possible combinations of 2 or 3 var-
iants (Table 6). No haplotype was associated with T2DM,
either when examined individually by HaploView 3.2 or
when tested for global differences in the haplotype distri-
bution between cases and controls by Phase 2.1.
We next examined the role of the three BTC coding vari-
ants in 107 individuals who had normal glucose tolerance
tests and who had undergone detailed assessment of insu-
lin sensitivity (SI) and insulin secretion using the FSIGT.
Only L124M altered the acute insulin response to glucose
(AIRg), with carrier status increasing the response from
481 mg/dl among L124 homozygotes to 661 mg/dl in
M124 carriers (p = 0.036; 95% CI 390 mg/dl – 593 mg/dl
for L124 homozygotes, 531 mg/dl to 822 mg/dl for M124
carriers). No other variant altered the AIRg, the ability of
the β-cell to compensate for insulin resistance (disposi-
tion index, DI = SI *AIRg), or in 40 individuals, the max-
imal insulin secretory response to arginine (AIRmax).
Likewise, genotype did not have any main effects on insu-
lin sensitivity, SI.
In exploratory analyses, we found evidence for an interac-
tion of L124M with BMI to influence SI (p = 0.042). Fur-
thermore, we tested for genotype effects on the additional
available traits of blood pressure (systolic and diastolic),
obesity (BMI, percent fat, waist:hip ratio), and lipids (trig-
lycerides, total cholesterol, HDL cholesterol) that were
not part of our initial hypothesis. We included gender,
genotype, and age in obesity models and gender, age, and
ln(BMI) in lipid models. We found genotype effects on
triglyceride levels (p = 0.007 for C7G and a trend to signif-
Table 4: Association of Betacellulin Coding Variants with Type 2 Diabetes in African American Subjects




C7G T/G 19 (Exon 1) 0.470 0.486 0.65
L44F C/T 130 (Exon 2) 0.105 0.083 0.28
L124M T/A 370 (Exon 4) 0.274 0.294 0.52
Frequencies are shown for the minor allele for each SNP. Variant is shown as major/minor allele, and name is likewise shown as common and 
uncommon amino acid, as originally described.
Table 3: Conditions and the Primers Sequences
SNP FORWARD PRIMER 5' to 3' REVERSE PRIMER 5' to 3' SEQUENCE PRIMER 5' to 3' Anneal Temp.
C7G *CGAAGAAGGAGGGAGACTT AATGACTTTCCTCCTGGTTTCCA GAGCTGGCGCCGCTGC 55°C
L44F TAGACTGTTTCACAATAAGC *ACAGTGACTGGTACCTTA GAAGTCCTGAAACTAATGGC 50°C
L124M CATTGGAGCAAGGTGTGAGA *CATGTGCAGACACCGATGA ACAGATTCTGGTGATTTGT 55°C
* Denotes addition of M13 primer sequence (5'-CACGACGTTGTAAAACGAC-3') to the 5' of primer.BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
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icance for L44M with p = .059), HDL cholesterol (p =
0.015 for C7G), and total cholesterol (p = 0.034 for
L124M). Marginal means for associated traits are shown
in Table 7.
Discussion
Considerable data support heritable defects in β-cell func-
tion leading to increased diabetes susceptibility, but to
date only the glutamine to lysine variant at position 23 in
the  β-cell potassium channel gene (KCNJ11 E23K) is
widely accepted [25]. That variant is uncommon in Afri-
can Americans. Variants that explain the high prevalence
of T2DM in African Americans are largely undiscovered.
Betacellulin is a strong candidate to cause β-cell dysfunc-
tion and T2DM given its apparent role as a β-cell growth
factor, the presence of three nonsynonymous coding vari-
ants, and the previous association of the C7G variant with
T2DM in African Americans [14]. Of the coding variants
examined in this study, C7G in exon 1 is in the signal pep-
tide. The minor allele, G7 in humans, is the wild type for
mouse, rat, and cow BTC genes. Hence, this position is not
conserved across species, and a functional role for this var-
iant is uncertain. The other two positions are conserved
across mouse, rat, and human, and might alter protein
structure and function. L124M in the transmembrane
domain is a conservative substitution, but L44F could
alter tertiary protein structure. However, neither variant
was associated with T2DM in the earlier study [14], nor do
we find evidence for an association with T2DM. We did
observe a modest association of homozygosity for L124
with reduced insulin secretion relative to M124 carrier sta-
tus, but this association would not be significant after
Bonferonni correction. Hence, our data do not support a
role for BTC variants in either T2DM susceptibility or
insulin secretion. BTC polymorphisms, either when con-
sidered individually or in haplotype combinations, were
not associated with T2DM. Indeed, we found no trend to
significance that would support the results of Silver et al
[14]. One limitation of our study is that our controls are
relatively young, and despite our attempt to screen for
family history and glucose tolerance, some controls may
still develop T2DM in the future, which would reduce the
power of our analysis. Furthermore, our analysis of insu-
lin secretion was based on only 107 individuals who had
undergone detailed phenotypic analysis; hence, power in
this group was potentially limiting. Nonetheless, only the
Table 6: Haplotype Analysis of Betacellulin Coding Variants
Combination Haplotype Case Frequency Control Frequency









L44F/L124M CT 0.624 0.627
CA 0.292 0.268
TT 0.081 0.098




Predicted haplotypes and frequencies in cases and controls are shown from the Phase 2.1 program. Similar results were obtained from HaploView 
3.2. Haplotypes with a predicted frequency of over 5% are shown, with the nucleotides as reported in Table 3. No differences approached 
significance.
Table 5: Genotypic Counts for Betacellulin Variants
Name Case Maj/Maj Case Maj/Min Case Min/Min Control Maj/Maj Control Maj/Min Control Min/Min
C7G 80 165 101 39 92 44
L44F 276 69 2 150 30 0
L 1 2 4 M 1 8 1 1 4 6 2 38 87 81 4
Raw genotype counts for each coding variant; note that counts vary due to some samples not successfully typed for one or more markers. Major 
alleles are listed first in Table 4.BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
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common homozygous state for L124M showed a trend to
an association with altered insulin secretion.
The frequency of the G7 allele was similar in our control
population to that reported by Silver et al. [14] (0.498 in
the present study, 0.45 by Silver). However, we found a
considerably higher frequency of this allele among Afri-
can American diabetic subjects than was reported by Silver
et al. (0.477 in the present study, 0.32 in the study of Sil-
ver et al.). The frequency of the L44F variant was similar
in both cases and controls in our two studies, whereas
L124M was somewhat more common in the present study
in both cases (0.27 in the current study, 0.22 in Silver et
al.) and controls (0.29 in the current study, 0.24 in Silver
et al.). These differences likely represent chance fluctua-
tions in allele frequencies given the size of the two studies.
Based on the allele frequencies reported by Silver et al, we
would have 85% power to find an association in our pop-
ulation, or based on the minor allele frequency of 0.32,
70% power to detect an OR of 1.6. However, using minor
allele frequencies from our study and an OR of 1.5, our
power was 62% for C7G, 65% for L124M, and only 33%
for L44F. Hence, we could easily have missed effects at any
of these variants of the size of PPARG [26] or KCNJ11 [27]
reported in previous studies in Caucasians (OR ≈ 1.2).
Alternatively, the differences may represent discrepant
allele frequencies based on geographic differences in Afri-
can American population structure [28]. Notably, the data
from Silver et al. showed marked differences in allele fre-
quency between Caucasian and African American popula-
tions for both C7G and L44F variants, but not for the
L124M variant. Hence, differences in population stratifi-
cation between Arkansas and Maryland populations
might explain the different results of our studies. We have
examined over 40 SNPs in candidate genes not specifically
selected for large differences between African American
and Caucasian frequencies, and found no significant dif-
ferences between cases and controls. More recently, we
examined 25 markers that show marked differences
between Caucasian and African American allele frequen-
cies [29], and similarly found no significant association
when tested by permutation (10,000 permutations; p >
0.08). Whereas we cannot completely exclude population
stratification without a larger marker set and a larger sam-
ple size, these data make this an unlikely explanation for
our lack of an association. Alternatively, differences in the
ascertainment of our case and control populations in
Arkansas and Baltimore might have resulted in different
environmental or genetic factors that interact with BTC
polymorphisms to increase the risk of T2DM.
We did find a significant effect of C7G on triglycerides and
HDL cholesterol. Marginal means support a gene dosage
effect. Furthermore, individuals homozygous for the com-
mon (C7) allele had the highest triglyceride levels, which
is consistent with the association with T2DM found by Sil-
ver et al. We found a trend towards an association for L44F
and triglycerides, with carrier status for the minor allele
showing a trend towards higher triglyceride levels. We
also found evidence for an association of reduced choles-
terol in carriers of the L124 allele. These findings were not
based on a priori hypotheses, and considering that we per-
formed 8 analyses for 3 SNPs, none of these findings
would reach statistical significance at a nominal p < 0.05
were a Bonferroni correction applied for 24 tests. Further-
more, a biological explanation for these findings is not
obvious. BTC is expressed in the gut, but a role in lipid
metabolism has not been reported. Hence, we cannot
exclude a type II error as the explanation for these find-
ings. This association will need confirmation in other
sample sets given these limitations.
Conclusion
We were unable to find a role for coding variants of the
BTC gene in either T2DM risk in African Americans or in
altered β-cell function in glucose tolerant, African Ameri-
can individuals. This finding contrasts with the earlier
report of an association of the C7G variant with T2DM in
African American subjects, but is consistent with the
apparently non-critical nature of this residue in the signal
peptide and the lack of association observed in Caucasian
individuals in the earlier study [14]. Based on an allelic
association using the case and control frequencies from
Table 7: Marginal Means for Traits Associated with Betacellulin Polymorphisms in Non-diabetic Individuals
Variant Trait Major/Major Major/Minor Minor/Minor p value
C7G triglycerides mmol/l 1.343 (1.131, 1.556) 1.025 (0.881, 1.169) 0.865 (0.653, 1.078) 0.007
C7G HDL cholesterol mmol/l 1.372 (1.229, 1.515) 1.280 (1.183, 1.377) 1.536 (1.392, 1.679) 0.015
L44F triglycerides mmol/l 0.953 (0.853, 1.066) 1.174 (0.853, 1.066) --- 0.059
L124M cholesterol mmol/l 4.675 (4.400, 4.951) 4.2551 (3.967, 4.544) --- 0.038
Marginal means are shown after correction for age, gender, and body mass index for each genotype. For C7G, 26 major homozygotes, 54 
heterozygotes, and 25 minor homozygotes were successfully typed. For L44P, we identified 60 homozygotes and 21 heterozygotes (no minor 
homozygotes observed). For L124M, we identified 57 major homozygotes, 45 heterozygotes, and 4 minor homozygous individuals. 1 Data are 
shown for Major/Minor + Minor/Minor combined. Lipid data are all in mmol/l. We provide means and 95% confidence intervals, converted to the 
linear scale for skewed variables. P values are for comparison of genotypes shown in the table, taken from the mixed effects model.BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
Page 7 of 8
(page number not for citation purposes)
Silver et al. and the sample size of the current study, we
had 98% power to reject the null hypothesis of no differ-
ence in allele frequencies. Unidentified gene-gene or gene-
environment interactions, differences in our ascertain-
ment methods, or differences in African American popu-
lations in different geographical regions may account for
our different findings.
Abbreviations
AIRG – acute insulin response to glucose
BMI: body mass index
BTC – betacellulin
DI – disposition index
SI – insulin sensitivity index
T2DM – type 2 diabetes
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SCE conceived the study design, oversaw patient ascer-
tainment, performed statistical analyses, and prepared the
manuscript. XW performed all typing, designed the assays,
and assisted with manuscript preparation. MAK assisted
with assay development and design, molecular typing,
and manuscript preparation. WSC prepared DNA for the
studies, assisted with assay design and genotyping. KDS
provided information on the SNPs and on University of
Maryland results and assisted in manuscript preparation.
Acknowledgements
This work was supported by grants DK39311 and DK54636 from the 
National Institutes of Health/NIDDK, by the Research Service of the 
Department of Veterans Affairs, and by grant support for subject ascertain-
ment from the American Diabetes Association. Subject ascertainment, 
DNA preparation, data management and statistical assistance were sup-
ported in part by grant M01RR14288 from National Institutes of Health/
National Center for Research Resources to the General Clinical Research 
Center (GCRC) of the University of Arkansas for Medical Sciences, College 
of Medicine. We thank the GCRC nursing staff for the support of intrave-
nous glucose tolerance tests, the GCRC laboratory for insulin assays and 
assistance with DNA extraction, Richard Harris for assistance with data 
management, Judith Johnson Cooper and Terri Hale for assistance with 
subject ascertainment.
References
1. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and
molecular implications for identifying diabetes genes.  Diabe-
tes Reviews 1997, 5:177-270.
2. Kahn SE: The relative contributions of insulin resistance and
beta-cell dysfunction to the pathophysiology of Type 2 diabe-
tes.  Diabetologia 2003, 46:3-19.
3. Ferrannini E, Mari A: Beta cell function and its relation to insulin
action in humans: a critical appraisal.  Diabetologia 2004,
47:943-956.
4. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history
of insulin secretory dysfunction and insulin resistance in the
pathogenesis of type 2 diabetes mellitus.  J Clin Invest 1999,
104:787-794.
5. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE: Heritability of pancre-
atic beta-cell function among nondiabetic members of Cau-
casian familial type 2 diabetic kindreds.  J Clin Endocrinol Metab
1999, 84:1398-1403.
6. Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamaki K,
Ehnholm C, Tuomilehto J, Collins FS, Bergman RN, Boehnke M:
Familiarity of quantitative metabolic traits in Finnish fami-
lies with non-insulin-dependent diabetes mellitus. Finland-
United States Investigation of NIDDM Genetics (FUSION)
Study investigators.  Hum Hered 1999, 49:159-168.
7. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag
A: Heritability of insulin secretion, peripheral and hepatic
insulin action, and intracellular glucose partitioning in young
and old danish twins.  Diabetes 2005, 54:275-283.
8. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes
mellitus – a genetically programmed failure of the beta cell
to compensate for insulin resistance.  N Engl J Med 1996,
334:777-783.
9. Yamamoto K, Miyagawa J, Waguri M, Sasada R, Igarashi K, Li M,
Nammo T, Moriwaki M, Imagawa A, Yamagata K, Nakajima H, Namba
M, Tochino Y, Hanafusa T, Matsuzawa Y: Recombinant human
betacellulin promotes the neogenesis of beta-cells and amel-
iorates glucose intolerance in mice with diabetes induced by
selective alloxan perfusion.  Diabetes 2000, 49:2021-2027.
10. Ishiyama N, Kanzaki M, Seno M, Yamada H, Kobayashi I, Kojima I:
Studies on the betacellulin receptor in pancreatic AR42J
cells.  Diabetologia 1998, 41:623-628.
11. Li L, Yi Z, Seno M, Kojima I: Activin A and betacellulin: effect on
regeneration of pancreatic beta-cells in neonatal streptozo-
tocin-treated rats.  Diabetes 2004, 53:608-615.
12. Miyagawa J, Hanafusa O, Sasada R, Yamamoto K, Igarashi K,
Yamamori K, Seno M, Tada H, Nammo T, Li M, Yamagata K, Nakajima
H, Namba M, Kuwajima M, Matsuzawa Y: Immunohistochemical
localization of betacellulin, a new member of the EGF family,
in normal human pancreas and islet tumor cells.  Endocr J
1999, 46:755-764.
13. Mashima H, Ohnishi H, Wakabayashi K, Mine T, Miyagawa J, Hanafusa
T, Seno M, Yamada H, Kojima I: Betacellulin and activin A coor-
dinately convert amylase-secreting pancreatic AR42J cells
into insulin-secreting cells.  J Clin Invest 1996, 97:1647-1654.
14. Silver K, Tolea M, Wang J, Pollin TI, Yao F, Mitchell BD: The exon 1
Cys7Gly polymorphism within the betacellulin gene is asso-
ciated with type 2 diabetes in African Americans.  Diabetes
2005, 54:1179-1184.
15. Silver KD, Magnuson VL, Tolea M, Wang J, Hagopian WA, Mitchell
BD: Association of a polymorphism in the betacellulin gene
with type 1 diabetes mellitus in two populations.  J Mol Med
2006.
16. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr: Dimin-
ished B cell secretory capacity in patients with noninsulin-
dependent diabetes mellitus.  J Clin Invest 1984, 74:1318-1328.
17. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM,
Bergman RN: MINMOD Millennium: a computer program to
calculate glucose effectiveness and insulin sensitivity from
the frequently sampled intravenous glucose tolerance test.
Diabetes Technol Ther 2003, 5:1003-1015.
18. Pacini G, Bergman RN: MINMOD: a computer program to cal-
culate insulin sensitivity and pancreatic responsivity from
the frequently sampled intravenous glucose tolerance test.
Comput Methods Programs Biomed 1986, 23:113-122.
19. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN,
Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr:
Quantification of the relationship between insulin sensitivity
and beta-cell function in human subjects: evidence for a
hyperbolic function.  Diabetes 1993, 42:1663-1672.
20. Ott J: Analysis of Human Genetic Linkage Third edition. Johns Hopkins
University Press, Baltimore and London; 1999. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2006, 7:62 http://www.biomedcentral.com/1471-2350/7/62
Page 8 of 8
(page number not for citation purposes)
21. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visu-
alization of LD and haplotype maps.  Bioinformatics 2005,
21:263-265.
22. Stephens M, Smith NJ, Donnelly P: A new statistical method for
haplotype reconstruction from population data.  Am J Hum
Genet 2001, 68:978-989.
23. Saad MF, Steil GM, Kades WW, Ayad MF, Elsewafy WA, Boyadjian R,
Jinagouda SD, Bergman RN: Differences between the tolbuta-
mide-boosted and the insulin-modified minimal model pro-
tocols.  Diabetes 1997, 46:1167-1171.
24. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B,
Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi
C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D:
The structure of haplotype blocks in the human genome.  Sci-
ence 2002, 296:2225-2229.
25. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G,
Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley
AT, Frayling TM: Large-scale association studies of variants in
genes encoding the pancreatic beta-cell KATP channel sub-
units Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the
KCNJ11 E23K variant is associated with type 2 diabetes.  Dia-
betes 2003, 52:568-572.
26. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC,
Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet
D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPAR-
gamma Pro12Ala polymorphism is associated with
decreased risk of type 2 diabetes.  Nat Genet 2000, 26:76-80.
27. Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, Holmkvist J,
Gaudet D, Hudson TJ, Schaffner SF, Daly MJ, Hirschhorn JN, Groop
L, Altshuler D: Haplotype structure and genotype-phenotype
correlations of the sulfonylurea receptor and the islet ATP-
sensitive potassium channel gene region.  Diabetes 2004,
53:1360-1368.
28. Tang H, Quertermous T, Rodriguez B, Kardia SL, Zhu X, Brown A,
Pankow JS, Province MA, Hunt SC, Boerwinkle E, Schork NJ, Risch NJ:
Genetic structure, self-identified race/ethnicity, and con-
founding in case-control association studies.  Am J Hum Genet
2005, 76:268-275.
29. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald
GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager
PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku
K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler
CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D,
Gilbert DA, O'Brien SJ, Reich D: A high-density admixture map
for disease gene discovery in african americans.  Am J Hum
Genet 2004, 74:1001-1013.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/7/62/prepub